Login to Your Account

Editas and Allergan ink eye disease deal, $90M up front

By Michael Fitzhugh
Staff Writer

Tuesday, March 14, 2017

Allergan plc has agreed to front the genome editing company Editas Medicine Inc. $90 million plus potential milestone payments for an exclusive option to license up to five ocular programs during a seven-year term.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription